Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Anna Karp

Dermatology New York, NY Doctor of Osteopathy

NPI 1487942223 CMS profile 3301894

291 Broadway Rm 1803, New York, NY 10007

Open in the dashboard

General payments

$13,643

544 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Anna Karp of New York, NY is reported in the CMS Open Payments database as having received $13,643 across 544 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 85th percentile of Dermatology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $4,599 138
2024 General $2,047 97
2023 General $2,956 127
2022 General $1,493 73
2021 General $1,438 65
2020 General $850 30
2019 General $261 14

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Anna Karp
  • Dermatology median
  • Middle half of Dermatology
  • National median

In program year 2025, general payments to Anna Karp were reported at $4,599. Among 10,363 Dermatology profiles paid that year, the median was $788 and the middle half received between $207 and $1,974.

Show as a table
Year Anna Karp Dermatology median Middle half National median
2019 $261 $454 $129–$1,240 $163
2020 $850 $235 $81–$756 $114
2021 $1,438 $377 $108–$1,108 $132
2022 $1,493 $514 $143–$1,391 $149
2023 $2,956 $607 $159–$1,674 $160
2024 $2,047 $751 $204–$1,903 $164
2025 $4,599 $788 $207–$1,974 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $2,857 93 payments
  2. Janssen Biotech, Inc. $2,614 104 payments
  3. Sun Pharmaceutical Industries Inc. $1,259 56 payments
  4. Lilly USA, LLC $987 46 payments
  5. Galderma Laboratories, L.P. $809 33 payments
  6. Pfizer Inc. $623 25 payments
  7. Dermavant Sciences, Inc. $541 16 payments
  8. Amgen Inc. $516 17 payments
  9. Regeneron Healthcare Solutions, Inc. $470 22 payments
  10. LEO Pharma Inc. $406 31 payments
  11. Other $2,561 101 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $12,163 537 payments
  2. Consulting Fee $1,050 1 payment
  3. Education $430 6 payments
Products named General payments · program years 2019–2025
  1. TREMFYA $2,552 100 payments
  2. BOTOX $1,050 1 payment
  3. SKYRIZI $941 47 payments
  4. TALTZ $906 43 payments
  5. Winlevi $717 28 payments
  6. VTAMA $571 17 payments
  7. RINVOQ $554 31 payments
  8. Otezla $516 17 payments
  9. ILUMYA $496 26 payments
  10. DUPIXENT $405 11 payments
  11. Other $6,057 279 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 11 drugs

Part D claims

318

Median for Dermatology: 534

Drug cost

$5,803

Median for Dermatology: $67,151

Branded share of claims

0%

Median for Dermatology: 8.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Tretinoin Generic 25 $1,752
Triamcinolone Acetonide Generic 86 $859
Clobetasol Propionate Generic 22 $820
Fluocinonide Generic 16 $684
Hydrocortisone Generic 13 $330
Minoxidil Generic 54 $313
Ketoconazole Generic 23 $299
Mupirocin Generic 38 $243
Clindamycin Phosphate Generic 16 $239
Mometasone Furoate Generic 11 $194

The 10 drugs with the highest cost, of 11 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,550 Part D prescribers listed as Dermatology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 26 billing codes

Paid by Medicare

$64,749

Of which drugs: $314

Medicare patients

248

Average age 74

Services billed

1,226

172 women, 76 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 59%
Arthritis 49%
Diabetes 23%
Osteoporosis 23%
Ischemic heart disease 20%
Cancer 17%
Depression 15%
Chronic kidney disease 10%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 18 59 $43

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 17 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
TREMFYA
  • Janssen Biotech, Inc. $597
$597 — —
SKYRIZI
  • AbbVie, Inc. $249
$249 — —
DUPIXENT
  • Regeneron Healthcare Solutions, Inc. $132
  • GENZYME CORPORATION $55
$187 — —
Otezla
  • Amgen Inc. $143
$143 — —
Winlevi
  • Sun Pharmaceutical Industries Inc. $127
$127 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 17 in the dashboard with a free account

Records

544 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Dermatology in New York

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record